Inogen (NASDAQ:INGN) Given "Hold" Rating at Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of Inogen (NASDAQ:INGN - Free Report) in a report published on Friday,Benzinga reports.

Separately, StockNews.com upgraded shares of Inogen from a "sell" rating to a "hold" rating in a research note on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $7.00.

Inogen Stock Performance

Shares of NASDAQ:INGN traded up $1.63 during trading hours on Friday, hitting $11.09. The stock had a trading volume of 937,830 shares, compared to its average volume of 336,162. The stock's fifty day simple moving average is $9.98 and its 200 day simple moving average is $9.36. Inogen has a 1-year low of $4.59 and a 1-year high of $13.33. The firm has a market capitalization of $263.05 million, a price-to-earnings ratio of -2.72 and a beta of 1.04.

Inogen (NASDAQ:INGN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The medical technology company reported ($0.24) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.31. Inogen had a negative net margin of 28.30% and a negative return on equity of 45.37%. The business had revenue of $88.77 million for the quarter, compared to analyst estimates of $82.50 million. During the same quarter last year, the business earned ($0.42) earnings per share. The business's revenue for the quarter was up 6.1% on a year-over-year basis. As a group, research analysts anticipate that Inogen will post -1.92 EPS for the current year.

Institutional Trading of Inogen

A number of large investors have recently added to or reduced their stakes in the business. Royce & Associates LP boosted its holdings in Inogen by 167.4% during the third quarter. Royce & Associates LP now owns 51,891 shares of the medical technology company's stock worth $503,000 after buying an additional 32,482 shares in the last quarter. Sanctuary Advisors LLC bought a new stake in Inogen during the second quarter worth approximately $651,000. B. Riley Wealth Advisors Inc. bought a new stake in Inogen during the second quarter worth approximately $457,000. Susquehanna Fundamental Investments LLC boosted its holdings in Inogen by 153.1% during the second quarter. Susquehanna Fundamental Investments LLC now owns 25,393 shares of the medical technology company's stock worth $206,000 after buying an additional 15,361 shares in the last quarter. Finally, Meros Investment Management LP boosted its holdings in Inogen by 1.6% during the second quarter. Meros Investment Management LP now owns 397,209 shares of the medical technology company's stock worth $3,229,000 after buying an additional 6,385 shares in the last quarter. 89.94% of the stock is currently owned by institutional investors.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.